Mechanistic studies indicate that MYSM1 may epigenetically enhance the expression of the miR-200 family and CDH1, thus inhibiting the PI3K/AKT signaling pathway and reducing the progression of colorectal cancer. The gene discussed is MYSM1; the disease is colorectal cancer.